Eli Lilly hits the accelerator in race to meet obesity demand

7 October 2022
lilly_big

Competition for Novo Nordisk’s (NOV: N) recently-approved weight loss drug Wegovy (semaglutide) is coming quickly, with Eli Lilly (NYSE: LLY) securing Fast Track designation for its rival therapy.

Marketed in diabetes as Mounjaro, tirzepatide is being developed as an option for adults with obesity, or overweight with weight-related comorbidities.

Based on its discussions with the US regulator, Lilly said it plans to initiate a rolling submission of a new drug application (NDA) later this year, based primarily on results from the Phase III SURMOUNT-1 and SURMOUNT-2 trials.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical